Cleaner air than an operating theater
A cleanroom is an enclosed space engineered to control the concentration of airborne particles, as well as temperature, humidity, air pressure, and the flow of personnel and materials. The air is continuously recirculated and filtered through high-efficiency particulate air (HEPA) or ultra-low penetration air (ULPA) filters, while the room is held at a differential pressure relative to its surroundings to ensure air flows outward—or inward, depending on containment needs—preventing contamination.
Its cleanliness level is classified under the ISO 14644-1 standard, ranging from ISO 1 (the most stringent) to ISO 9. The contrast with an ordinary environment is stark: typical office air contains millions of particles per cubic meter, whereas an ISO 5 cleanroom permits only a few thousand particles measuring 0.5 micrometers or larger. Furthermore, within the European pharmaceutical sector, Good Manufacturing Practice (GMP) guidelines enforce their own grading classification, ranging from Grade A to D.
Why demand such rigorous controls? Because in certain processes, a single microscopic particle—invisible to the naked eye—can ruin an entire batch. The primary applications include:
- Semiconductors and microelectronics, where a single speck of dust can disable a circuit.
- Pharmaceutical and biotechnological manufacturing, where contamination jeopardizes patient safety.
- Medical devices and implantables.
- Precision optics, photonics, and aerospace components.
- Nanotechnology and advanced materials, where work occurs at scales where the ambient environment itself directly impacts experimental outcomes.
Put simply, a cleanroom is an environment where external uncertainty is minimized, ensuring that the only variable is the experiment itself.
Where it is decided whether a technology takes off or stalls
What struck us most during the visit was that a cleanroom is far more than a mere technical asset—it is a critical determinant of successful technology transfer. This intersects directly with our core mission at PQNO.
A key part of our work involves guiding research outcomes along the commercialization pathway—through market studies, technology valuation, and business planning. Along this journey, a recurring question emerges—one almost never addressed in grant proposals: where will this actually be manufactured? where will this actually be manufactured? A prototype that performs in a controlled laboratory setting does not guarantee reproducible, cost-effective production at the quality standards demanded by industrial clients or regulatory bodies. This gulf between “it works” and “it can be reliably manufactured” represents what many term the valley of death in technology transfer; for technologies reliant on controlled environments, the cleanroom sits right at its center.
This carries direct implications for our analysis. Manufacturing requirements dictate the underlying business model: if production demands a cleanroom environment, the cost structure, upfront capital expenditure (CapEx), and necessary strategic partnerships change entirely. They also dictate technology valuation. Two developments with comparable scientific results can yield vastly different valuations if one can be scaled using existing infrastructure while the other requires unbudgeted capital outlays. Finally, they dictate time-to-market; facility scheduling, process qualification, and regulatory validation invariably extend timelines far beyond initial projections.
That is why, when assessing a technological opportunity, inquiring about the required infrastructure is far from a late-stage technical detail—it is an integral component of the market analysis itself.
Shared infrastructure as an innovation policy
There is a third dimension worth putting on the table: who can actually afford a cleanroom. Building and maintaining one is capital-intensive. It demands substantial upfront CapEx, continuous energy consumption, highly skilled personnel, and regular compliance re-certifications. For a deeptech startup—or a research team with a freshly minted patent—this represents an almost insurmountable barrier to entry if borne entirely on their own.
That is precisely why shared access to infrastructure—such as cleanrooms at universities, technology centers, or open-access public facilities—serves as one of the most critical, yet least visible, levers of technology transfer. Under a viable open-access model, a spin-off can validate its process without burning through its initial funding round on capital equipment. Where such access is lacking, promising technologies founder midway for want of a facility to produce their initial runs.
This reveals a key systemic tension worthy of debate. Shared infrastructure optimizes efficiency across the broader innovation ecosystem, yet its management raises open questions: how to prioritize facility access, how to safeguard intellectual property for user entities, and how to structure fee schedules that ensure long-term financial sustainability without pricing out early-stage projects. There is no one-size-fits-all answer, and approaches vary significantly across jurisdictions, institutions, and industry verticals. What remains clear, however, is that funding scientific capability without equal investment in the capacity to scale and manufacture leaves the value chain fundamentally incomplete.
COMPASS’ CONCLUSSION
A cleanroom is a space defined by what it excludes: dust, variability, noise. Yet its value to the innovation ecosystem lies in the exact opposite—in what it allows to be included. It enables an idea to transition from a mere research result into a tangible product, allowing innovators to prove with empirical data, rather than mere expectations, that something truly works.
For those of us working in technology transfer, the visit offered a timely reminder: the market does not buy discoveries—it buys things that can be manufactured successfully, time and time again. And for that, sometimes you have to start by controlling the air.